@prefix rdf: . @prefix ns1: . @prefix ns2: . ns1:DB05294 rdf:type ns2:Drug ; ns2:description "Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. "@en ; ns2:dosage , ; ns2:generalReferences "# Bates D: ZD-6474. AstraZeneca. Curr Opin Investig Drugs. 2003 Dec;4(12):1468-72. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14763134 # Ton GN, Banaszynski ME, Kolesar JM: Vandetanib: A novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer. Am J Health Syst Pharm. 2013 May 15;70(10):849-55. doi: 10.2146/ajhp120253. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/23640345 # Andriamanana I, Gana I, Duretz B, Hulin A: Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 May 1;926:83-91. doi: 10.1016/j.jchromb.2013.01.037. Epub 2013 Mar 16. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/23562906"@en ; ns2:group "approved"@en ; ns2:halfLife "Median half life of 19 days."@en ; ns2:indication "Vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure. "@en . @prefix owl: . @prefix ns4: . ns1:DB05294 owl:sameAs ns4:DB05294 . @prefix dcterms: . ns1:DB05294 dcterms:title "Vandetanib"@en . @prefix adms: . @prefix ns7: . ns1:DB05294 adms:identifier ns7:DB05294 . @prefix ns8: . ns1:DB05294 adms:identifier ns8:D06407 , , . @prefix ns9: . ns1:DB05294 adms:identifier ns9:Vandetanib ; ns2:mechanismOfAction "ZD-6474 is a potent and selective inhibitor of VEGFR (vascular endothelial growth factor receptor), EGFR (epidermal growth factor receptor) and RET (REarranged during Transfection) tyrosine kinases. VEGFR- and EGFR-dependent signalling are both clinically validated pathways in cancer, including non-small-cell lung cancer (NSCLC). RET activity is important in some types of thyroid cancer, and early data with vandetanib in medullary thyroid cancer has led to orphan-drug designation by the regulatory authorities in the USA and EU. "@en ; ns2:patent , ; ns2:routeOfElimination "About 69% was recovered following 21 days after a single dose of vandentanib. 44% was found in feces and 25% in urine. "@en ; ns2:synonym "ZD6474"@en , "4-BROMO-2-fluoro-N-[(4e)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4(1H)-ylidene]aniline"@en , "N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinamine"@en , "N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine"@en , "Zactima"@en , "ZD 6474"@en , "4-quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-"@en ; ns2:volumeOfDistribution "Vd of about 7450 L."@en ; ns2:proteinBinding "Protein binding of about 90%."@en ; ns2:IUPAC-Name ; ns2:InChI ; ns2:Molecular-Formula ; ns2:Molecular-Weight ; ns2:Monoisotopic-Weight ; ns2:SMILES ; ns2:Water-Solubility , ; ns2:logP , ; ns2:logS . @prefix ns10: . @prefix ns11: . ns1:DB05294 ns10:hasATCCode ns11:L01XE12 ; ns2:H-Bond-Acceptor-Count ; ns2:H-Bond-Donor-Count ; ns2:InChIKey ; ns2:Polar-Surface-Area--PSA- ; ns2:Polarizability ; ns2:Refractivity ; ns2:Rotatable-Bond-Count ; ns2:absorption "Slow- peak plasma concentrations reached at a median 6 hours. On multiple dosing, Vandetanib accumulates about 8 fold with steady state reached after around 3 months. "@en ; ns2:affectedOrganism "Humans and other mammals"@en ; ns2:casRegistryNumber "443913-73-3"@en ; ns2:Bioavailability ; ns2:Ghose-Filter ; ns2:MDDR-Like-Rule ; ns2:Number-of-Rings ; ns2:Physiological-Charge ; ns2:Rule-of-Five ; ns2:Traditional-IUPAC-Name ; ns2:pKa--strongest-acidic- ; ns2:pKa--strongest-basic- .